drugset / Trial / NCT01932151
Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis
NaSingle-groupOpen-labelTreatment
Summary
Type 1 Hepatorenal syndrome (type-1 HRS) is a severe complication of patients with advanced cirrhosis characterized by marked renal failure and is associated with a very poor prognosis. Type-1 HRS is often precipitated by a bacterial infection, though it may occur spontaneously. It has been demonstrated that vasoconstrictor agents plus albumin are effective in the reversal of the renal failure. A large number of studies have shown that terlipressin improves renal function in patients with type 1 HRS; treatment is effective in 50-75% of patients approximately. Currently there are no specific studies about the treatment of type-1 HRS with ongoing infections.
Timeline
- Start
- 2012-12
- Primary completion
- 2013-07
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin | Protein / enzyme biologic | 40 g | — |
| Subject | Terlipressin | Peptide | 1 mg | Intravenous |
| Subject | Terlipressin | Peptide | 2 mg | Intravenous |